Breakthrough formulation helps reduce the risk of exposure using a non-hazardous formulation and leakproof format during transport and processing
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
In a European work-sharing procedure (WSP), Glucophage was approved as the first oral anti-diabetic medication to be used safely from conception to birth
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
The first wave of shipments includes several countries, such as Germany, France and Austria
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
The medicine is the first and only oral MET inhibitor to receive CHMP positive opinion in Europe for adult patients with advanced NSCLC harbouring alterations leading to METex14 skipping
Subscribe To Our Newsletter & Stay Updated
